Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer

2.1 Pembrolizumab (Keytruda, Merck Sharp and Dohme) has a marketing authorisation for use in combination with chemotherapy 'for the treatment of locally recurrent unresectable or metastatic triple‑negative breast cancer in adults whose tumours express PD‑L1 with a CPS more than or equal to 10 and who have not received prior chemotherapy for metastatic disease'.

2.2 The dosage schedule is available in the summary of product characteristics for pembrolizumab.

2.3 The company's list price is £2,630 per 100‑mg solution for infusion vial (excluding VAT, BNF online accessed January 2022).

2.4 The company has a commercial arrangement. This makes pembrolizumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.